Kymera Therapeutics, Inc.
No SEC Form 4 filings for $KYMR in the last 30 days.
Kymera Therapeutics (NASDAQ: KYMR) reported Q2 2026 results and updated its pipeline. Enrollment in KT-621 BROADEN2 Phase 2b atopic dermatitis finished nearly six months early, shifting topline data to year-end 2026 and Phase 3 start to mid-2027. KT-621 asthma data is due late 2027. KT-579 Phase 1 data is expected 4Q26. Cash was $1.5B as of June 30, 2026.
Kymera Therapeutics (KYMR) shares rose about 1% to $105.48 after Q2 results. The company reported collaboration revenue of $65.0m versus $11.5m a year earlier, with net loss of $61.2m (vs $76.6m) and trailing 12-month net loss of $299.6m. Management said no further 2026 collaboration revenue is expected without new milestones.
Kymera Therapeutics said its Phase 2b BROADEN2 trial of KT-621, an oral STAT6 degrader for atopic dermatitis, closed enrollment about six months early, moving topline results from mid-2027 to year-end 2026 and compressing Phase 3 start to mid-2027. The company cited Phase 1 data showing up to 98% STAT6 degradation in peripheral blood.
Over the past 7 days, alphai's AI scored 6 news stories mentioning KYMR (Kymera Therapeutics, Inc.). Coverage has skewed bullish: 4 bullish, 2 neutral, and 0 bearish.
Recent KYMR coverage spans earnings, financial news and technology.
The accelerated KT-621 AD enrollment and pulled topline timeline are a near-term catalyst for KYMR’s clinical execution narrative and risk profile.
The article frames a durability risk: partnership-driven revenue is not recurring, while cash burn and losses persist.
Faster enrollment increases the probability of earlier efficacy readouts, potentially accelerating valuation rerating for KT-621 and the STAT6 degrader platform.
Higher collaboration revenue and faster KT-621 trial enrollment are near-term positives, but the story remains execution and cash-runway dependent.
The key tradable change is the timeline shift for KT-621 BROADEN2, which increases near-term probability of earlier efficacy visibility and earlier Phase 3 start.
alphai scores every news story that mentions KYMR with an AI model for sentiment and relevance, and aggregates insider trades from Kymera Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kymera Therapeutics (NASDAQ: KYMR) reported Q2 2026 results and updated its pipeline. Enrollment in KT-621 BROADEN2 Phase 2b atopic dermatitis finished nearly six months early, shifting topline data to year-end 2026 and Phase 3 start to mid-2027. KT-621 asthma data is due late 2027. KT-579 Phase 1 data is expected 4Q26. Cash was $1.5B as of June 30, 2026.
6 min readKymera Therapeutics (KYMR) shares rose about 1% to $105.48 after Q2 results. The company reported collaboration revenue of $65.0m versus $11.5m a year earlier, with net loss of $61.2m (vs $76.6m) and trailing 12-month net loss of $299.6m. Management said no further 2026 collaboration revenue is expected without new milestones.
6 min readKymera Therapeutics said its Phase 2b BROADEN2 trial of KT-621, an oral STAT6 degrader for atopic dermatitis, closed enrollment about six months early, moving topline results from mid-2027 to year-end 2026 and compressing Phase 3 start to mid-2027. The company cited Phase 1 data showing up to 98% STAT6 degradation in peripheral blood.
5 min readKymera Therapeutics (KYMR) reported Q2 net loss of $61.21M, or $0.62/share, narrower than $76.61M, or $0.95/share a year earlier, mainly due to $65M collaboration revenue. The quarter included a $45M Gilead option fee and $20M Sanofi milestone. Cash totaled $1.5B at June 30, 2026.
4 min readKymera Therapeutics, Inc. (KYMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 kymr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data e
6 min readKymera Therapeutics appointed Terence Rooney, MD as Chief Medical Officer, replacing Jared Gollob, who will retire and advise through year-end, according to the company. The article links the hire to Kymera’s oral immunology program, KT 621, noting early completion of enrollment in Phase 2b BROADEN2 for atopic dermatitis and highlighting forecast revenue of $44.7M and earnings of $7.6M by 2029.
6 min readAnalysts issued multiple rating changes. Humana (HUM) was upgraded by Leerink to Outperform with a $513 target and by Piper Sandler to Overweight with a $463 target. Bloom Energy (BE), Sprouts (SFM), uniQure (QURE), and Core Scientific (CORZ) also saw upgrades. Las Vegas Sands (LVS) was downgraded to Hold by Argus. Other actions included P&G (PG), SiteOne (SITE), Capricor (CAPR), and Fannie Mae (FNMA).
3 min readKymera Therapeutics (NASDAQ: KYMR) will report Q2 2026 financial results on Aug 5, 2026, with a webcast and video call at 8:30 a.m. ET. The company also appointed Terence Rooney as Chief Medical Officer on July 27, 2026, following Jared Gollob’s retirement, to lead global clinical development for its oral immunology portfolio.
3 min readKymera Therapeutics, Inc. (KYMR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001815442 0001815442 2026-07-27 2026-07-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27,
3 min readWall Street analysts issued multiple rating changes. JPMorgan raised American Express (AXP) to Overweight, PT $400. Truist upgraded Biogen (BIIB) to Buy, PT $235, citing upcoming Phase 2 and Phase 3 readouts. JPMorgan also raised Keysight (KEYS) to Overweight, PT $400. Other actions included upgrades for Humana (HUM) and downgrades for Papa John’s (PZZA) and Best Buy (BBY).
4 min read
